GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo trial offers hope for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called PT886 (Spevatamig) in people with advanced stomach, pancreatic, or bile duct cancers that cannot be removed by surgery or have spread. The trial has two parts: first, finding the safest dose of PT886 alone, then testing it combined with chemothe…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New drug targets tough stomach cancer in early trial
Disease control Recruiting nowThis study tests a new drug called HLX43 in 60 people with advanced stomach or gastroesophageal junction cancer that has spread. The drug is designed to target and attack cancer cells while limiting harm to healthy cells. The goal is to find the best dose and see if it shrinks tu…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New hope for stomach cancer: drug combo trial launches
Disease control Recruiting nowThis study tests a new drug called utidelone combined with standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the combination helps patients live longer and controls the disease better…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC